Interestingly,EX-527 (a selective SIRT1 inhibitor) and TM (a selective SIRT2 inhibitor)exhibit much lower inhibition in DLBCL cells compared to that of SJ-106C,indicating that SJ-106C’s robust antiproliferative activityis mainly through SIRT3 inhibition in DLBCL cells (Figure S6B). The gene discussed is SIRT3; the disease is diffuse large B-cell lymphoma.